Велика Британія - англійська - MHRA (Medicines & Healthcare Products Regulatory Agency)

wockhardt uk ltd - risperidone - oral solution - 1mg/1ml

Велика Британія - англійська - MHRA (Medicines & Healthcare Products Regulatory Agency)

rosemont pharmaceuticals ltd - citalopram hydrochloride - oral drops - 40mg/1ml

Велика Британія - англійська - MHRA (Medicines & Healthcare Products Regulatory Agency)

advanz pharma - citalopram hydrochloride - oral drops - 40mg/1ml

Велика Британія - англійська - MHRA (Medicines & Healthcare Products Regulatory Agency)

rosemont pharmaceuticals ltd - risperidone - oral solution - 1mg/1ml

Велика Британія - англійська - MHRA (Medicines & Healthcare Products Regulatory Agency)

milpharm ltd - risperidone - oral solution - 1mg/1ml

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

jazz pharmaceuticals anz pty ltd - daunorubicin, quantity: 44 mg; cytarabine, quantity: 100 mg - injection, powder for - excipient ingredients: cholesterol; sucrose; distearoylphosphatidylglycerol; trolamine; copper gluconate; distearoylphosphatidylcholine - vyxeos is indicated for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukaemia (t-aml) or aml with myelodysplasia-related changes (aml-mrc)

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

gilead sciences pty ltd - amphotericin b, quantity: 50 mg - injection, powder for - excipient ingredients: hydrogenated soy phosphatidylcholine; sucrose; dl-alpha-tocopherol; distearoylphosphatidylglycerol; sodium succinate; cholesterol - indications: ambisome is indicated for: prophylaxis in liver transplant patients at risk of systemic candida, aspergillus and cryptococcus infections, and for the treatment of systemic fungal infections caused by organisms susceptible to amphotericin b (see clinical trials). ambisome is indicated for the treatment of visceral leishmaniasis. clinical studies of efficacy in visceral leishmaniasis are limited to leishmania infantum. indicated as at 8 september 2003 :ambisome is indicated for: prophylaxis in liver transplant patients at risk of systemic candida, aspergillus and cryptococcus infections, and for the treatment of systemic fungal infections caused by organisms susceptible to amphotericin b (see clinical trials). ambisome is indicated for empirical treatment of presumed fungal infections in febrile neutropaenic patients whose fever has failed to respond to broad spectrum antibiotic treatment. ambisome is indicated for the treatment of visceral leishmaniasis. clinical studies of efficacy in visceral leishmaniasis are limited to leishmania infantum.

Мальта - англійська - Medicines Authority

dompe farmaceutici spa via san martino 12, 20122, milan, italy - carbocisteine - powder for oral solution - carbocisteine 1.35 g - cough and cold preparations

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - parecoxib sodium, quantity: 42.36 mg - injection, powder for - excipient ingredients: dibasic sodium phosphate; phosphoric acid; sodium hydroxide - for a single peri-operative dose for the management of post-operative pain.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - parecoxib sodium, quantity: 42.36 mg - injection, powder for - excipient ingredients: phosphoric acid; dibasic sodium phosphate; sodium hydroxide - for a single peri-operative dose for the management of post-operative pain.